Friday, April 12, 2024 8:39:05 AM
"The definite subscription agreements were executed based on the closing price of RenovoRx’s common stock on April 4, 2024, and the private placement is expected to close on April 11, 2024, subject to customary closing conditions. Newbridge Securities Corporation is acting as sole placement agent for the transaction."
Recent RNXT News
- RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024 • Business Wire • 05/02/2024 01:00:00 PM
- RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement • Business Wire • 04/18/2024 12:30:00 PM
- RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting • Business Wire • 04/16/2024 12:30:00 PM
- RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026 • Business Wire • 04/15/2024 12:00:00 PM
- RenovoRx Announces $11.1 Million at Market Private Placement • Business Wire • 04/08/2024 12:30:00 PM
- RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024 • Business Wire • 04/05/2024 12:30:00 PM
- RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024 • Business Wire • 03/12/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:28:31 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:26:04 PM
- RenovoRx Highlights Key Leadership Promotions • Business Wire • 03/08/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 12:46:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:30:41 PM
- RenovoRx CEO Issues Letter to Shareholders • Business Wire • 02/06/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 12:33:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 11:57:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 11:32:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 11:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 02:06:07 PM
- RenovoRx Closes $6.1 Million Private Placement • Business Wire • 01/29/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 02:50:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 02:50:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 02:50:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 01:30:33 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM